Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 50:2243-2248, doi:10.1016/j.jacc.2007.08.033 (Published online 14 November 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.08.033v1
50/23/2243    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Povsic, T. J.
Right arrow Articles by Peterson, E. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Povsic, T. J.
Right arrow Articles by Peterson, E. D.

CLINICAL RESEARCH: ENDOTHELIAL PROGENITOR CELLS

Circulating Progenitor Cells Can Be Reliably Identified on the Basis of Aldehyde Dehydrogenase Activity

Thomas J. Povsic, MD, PhD*,*, Katherine L. Zavodni, BS*, Francine L. Kelly, BS*, Shoukang Zhu, PhD*, Pascal J. Goldschmidt-Clermont, MD, FACC{ddagger}, Chunming Dong, MD* and Eric D. Peterson, MD, MPH, FACC{dagger}

* Division of Cardiology, Duke University Medical Center, Durham, North Carolina
{dagger} Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
{ddagger} Miller School of Medicine, University of Miami, Miami, Florida

Manuscript received April 9, 2007; revised manuscript received August 23, 2007, accepted August 27, 2007.

* Reprint requests and correspondence: Dr. Thomas J. Povsic, Box 3126, Duke University Medical Center, Durham, North Carolina 27710. (Email: povsi001{at}mc.duke.edu).

Objectives: Our objective was to develop and assess a novel endogenous progenitor cell (EPC) assay based on aldehyde dehydrogenase (ALDH) activity, and to define the relationship of ALDH-bright (ALDHbr) cells with previously defined EPCs, patient age, and extent of coronary artery disease.

Background: Accurate assessment of circulating EPCs is of significant interest, yet current assays have limitations. Progenitor cells display high levels of ALDH activity. An assay based on ALDH activity may offer a simple means for enumerating EPCs.

Methods: We simultaneously determined the numbers of EPCs based on ALDH activity and cell surface expression of CD133, CD34, and vascular endothelial growth factor receptor-2 in 110 patients undergoing cardiac catheterization. We assessed the reproducibility of these estimates, correlation among EPC assays, and the association of ALDHbr numbers with age and disease severity.

Results: Aldehyde dehydrogenase-bright cells were easily identified in nonmobilized peripheral blood with median and mean frequencies of 0.041% and 0.074%, respectively. Aldehyde dehydrogenase-bright cells expressed CD34 or CD133 cell surface markers (57.0% and 27.1%, respectively), correlated closely with CD133+CD34+ cells (r = 0.72; p < 0.001), and differentiated into endothelial cells with greater efficiency than CD133+CD34+ cells. Aldehyde dehydrogenase-bright cell numbers were inversely associated with patient age and coronary disease severity.

Conclusions: Aldehyde dehydrogenase activity represents a novel simplified method for quantifying EPCs. The correlation of ALDHbr cells with clinical factors and outcomes warrants further study.

Abbreviations and Acronyms
  ALDH = aldehyde dehydrogenase
  ALDHbr = aldehyde dehydrogenase-bright
  CAD = coronary artery disease
  EPC = endogenous progenitor cell
  FACS = fluorescence-activated cell sorting
  MNC = mononuclear cell
  VEGFR = vascular endothelial growth factor receptor




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
P. Wenzel, E. Schulz, T. Gori, M. A. Ostad, F. Mathner, S. Schildknecht, S. Gobel, M. Oelze, D. Stalleicken, A. Warnholtz, et al.
Monitoring White Blood Cell Mitochondrial Aldehyde Dehydrogenase Activity: Implications for Nitrate Therapy in Humans
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 63 - 71.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. Ma, K. W. Chan, T. K.-W. Lee, K. H. Tang, J. Y.-H. Wo, B.-J. Zheng, and X.-Y. Guan
Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations
Mol. Cancer Res., July 1, 2008; 6(7): 1146 - 1153.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. S. Hart and W. S. El-Deiry
Invincible, but Not Invisible: Imaging Approaches Toward In Vivo Detection of Cancer Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2901 - 2910.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement